Lucentis (Ranibizumab) Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Description

Lucentis (ranibizumab) is a prescription medication used to treat eye disorders involving abnormal blood vessel growth in the retina, including conditions such as age-related macular degeneration and diabetic retinopathy. It is a recombinant monoclonal antibody fragment designed to inhibit vascular endothelial growth factor (VEGF), a protein that promotes abnormal blood vessel formation in the retina.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types in the lucentis (ranibizumab) market are the single-use prefilled syringe and the single-use glass vial. The single-use prefilled syringe is a device prefilled with a precise dose of the medication, ready for immediate use, allowing for more convenient and accurate administration. Key applications of Lucentis include age-related macular degeneration, diabetic retinopathy, retinal vein occlusion, myopic choroidal neovascularization, and uveitis. The end-users of Lucentis are primarily hospitals, clinics, ambulatory surgical centers, and other healthcare settings.

The lucentis (ranibizumab) market research report is one of a series of new reports from The Business Research Company that provides lucentis (ranibizumab) market statistics, including lucentis (ranibizumab) industry global market size, regional shares, competitors with a lucentis (ranibizumab) market share, detailed lucentis (ranibizumab) market segments, market trends, and opportunities, and any further data you may need to thrive in the lucentis (ranibizumab) industry. This lucentis (ranibizumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The lucentis (ranibizumab) market size is expected to see strong growth in the next few years. It will grow to $4,633.3 million in 2029 at a compound annual growth rate (CAGR) of 5%. The growth in the forecast period can be attributed to increasing incidence of diabetic retinopathy (DR) and diabetic macular edema (DME), advancements in treatment protocols and combination therapies, aging population and rising prevalence of retinal diseases, expansion of market access in emerging markets, ongoing clinical research and potential new indications. Major trends in the forecast period include shift toward longer-interval dosing and maintenance treatment, growing adoption of biosimilars and alternative treatments, increase in personalized medicine approaches for retinal diseases, rising demand in emerging markets due to improving healthcare access, integration of digital health solutions in treatment monitoring.

The rising prevalence of eye-related disorders is expected to drive the growth of the lucentis (ranibizumab) market. Eye-related disorders encompass various conditions that impair the proper functioning of the eyes, and their prevalence is increasing due to factors such as aging, genetic predisposition, lifestyle choices like smoking and poor diet, and environmental influences such as prolonged sun exposure and excessive digital screen use. Lucentis works by inhibiting vascular endothelial growth factor (VEGF), which is responsible for abnormal blood vessel growth and leakage in the retina, common causes of conditions like age-related macular degeneration (AMD) and diabetic macular edema (DME). According to the National Eye Institute, 2.2 million Americans will be blind by 2030, indicating a growing need for treatments like Lucentis. Thus, the rising prevalence of eye-related disorders is driving the market for lucentis.

The rise in healthcare spending is a key factor propelling the growth of the lucentis (ranibizumab) market. Healthcare spending, which includes financial resources allocated by individuals, governments, and insurers for healthcare services and products, is increasing due to factors like an aging population, advancements in medical technology, and the rising prevalence of chronic diseases. This growth in healthcare expenditure helps to ensure that treatments like Lucentis are accessible, enabling widespread use in treating retinal diseases such as AMD and DME. It also supports the reimbursement, coverage, and distribution of the drug, ultimately improving patient outcomes and reducing the long-term burden of vision loss. For instance, healthcare spending in the UK increased by 5.6% in 2023, reflecting a larger trend of rising healthcare investments that support the lucentis market.

A key trend in the lucentis (ranibizumab) market is the development of biosimilars to offer more affordable alternatives to the branded product. Biosimilars are biologic medical products that are highly similar to an already approved reference biologic in terms of structure, efficacy, and safety, with no clinically meaningful differences. For example, in April 2024, Formycon AG and Bioeq AG launched FYB201, a biosimilar version of Lucentis, in Canada and Switzerland. Known as Ranopto and Ranivisio in these markets, respectively, the biosimilar provides a more cost-effective option for patients suffering from retinal diseases. Like Lucentis, FYB201 inhibits VEGF-A, a protein that causes abnormal blood vessel growth in the retina, leading to conditions like swelling and vision impairment. The approval and launch of such biosimilars contribute to market growth by expanding access to treatment.

Major players operating in the lucentis (ranibizumab) market are F.Hoffmann-La Roche Ltd, Novartis AG.

North America was the largest region in the lucentis (ranibizumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in lucentis (ranibizumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the lucentis (ranibizumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lucentis (ranibizumab) market consists of sales of lucentis intravitreal injection and lucentis for biosimilars. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Lucentis (Ranibizumab) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on lucentis (ranibizumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for lucentis (ranibizumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The lucentis (ranibizumab) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Single-use Prefilled Syringe; Single-use Glass Vial
2) By Application: Age-related Macular Degeneration; Diabetic Retinopathy; Retinal Vein Occlusion; Myopic Choroidal Neovascularization; Uveitis
3) By End-User: Hospitals; Clinics; Ambulatory Surgical Centers; Other End-Users
Companies Mentioned: F.Hoffmann-La Roche Ltd; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r33094

1. Executive Summary

2. Lucentis (Ranibizumab) Market Characteristics

3. Lucentis (Ranibizumab) Market Biologic Drug Characteristics

3.1. Molecule Type
3.2. Route Of Administration (ROA)
3.3. Mechanism Of Action (MOA)
3.4. Safety And Efficacy

4. Lucentis (Ranibizumab) Market Trends And Strategies

5. Lucentis (Ranibizumab) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Lucentis (Ranibizumab) Growth Analysis And Strategic Analysis Framework

6.1. Global Lucentis (Ranibizumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.2. Analysis Of End Use Industries
6.3. Global Lucentis (Ranibizumab) Market Growth Rate Analysis
6.4. Global Lucentis (Ranibizumab) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
6.5. Global Lucentis (Ranibizumab) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
6.6. Global Lucentis (Ranibizumab) Total Addressable Market (TAM)

7. Global Lucentis (Ranibizumab) Market Pricing Analysis & Forecasts

8. Lucentis (Ranibizumab) Market Segmentation

8.1. Global Lucentis (Ranibizumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Single-use Prefilled Syringe
Single-use Glass Vial
8.2. Global Lucentis (Ranibizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Age-related Macular Degeneration
Diabetic Retinopathy
Retinal Vein Occlusion
Myopic Choroidal Neovascularization
Uveitis
8.3. Global Lucentis (Ranibizumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Ambulatory Surgical Centers
Other End-Users

9. Global Lucentis (Ranibizumab) Market Epidemiology Of Clinical Indications

9.1. Drug Side Effects
9.2. Incidence And Prevalence of Clinical Indications

10. Lucentis (Ranibizumab) Market Regional And Country Analysis

10.1. Global Lucentis (Ranibizumab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. Global Lucentis (Ranibizumab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Lucentis (Ranibizumab) Market

11.1. Asia-Pacific Lucentis (Ranibizumab) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Lucentis (Ranibizumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Asia-Pacific Lucentis (Ranibizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Asia-Pacific Lucentis (Ranibizumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Lucentis (Ranibizumab) Market

12.1. China Lucentis (Ranibizumab) Market Overview
12.2. China Lucentis (Ranibizumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
12.3. China Lucentis (Ranibizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
12.4. China Lucentis (Ranibizumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Lucentis (Ranibizumab) Market

13.1. India Lucentis (Ranibizumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. India Lucentis (Ranibizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. India Lucentis (Ranibizumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Lucentis (Ranibizumab) Market

14.1. Japan Lucentis (Ranibizumab) Market Overview
14.2. Japan Lucentis (Ranibizumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. Japan Lucentis (Ranibizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. Japan Lucentis (Ranibizumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Lucentis (Ranibizumab) Market

15.1. Australia Lucentis (Ranibizumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.2. Australia Lucentis (Ranibizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Australia Lucentis (Ranibizumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Lucentis (Ranibizumab) Market

16.1. South Korea Lucentis (Ranibizumab) Market Overview
16.2. South Korea Lucentis (Ranibizumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. South Korea Lucentis (Ranibizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.4. South Korea Lucentis (Ranibizumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Lucentis (Ranibizumab) Market

17.1. Western Europe Lucentis (Ranibizumab) Market Overview
17.2. Western Europe Lucentis (Ranibizumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Western Europe Lucentis (Ranibizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.4. Western Europe Lucentis (Ranibizumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Lucentis (Ranibizumab) Market

18.1. UK Lucentis (Ranibizumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. UK Lucentis (Ranibizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. UK Lucentis (Ranibizumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Lucentis (Ranibizumab) Market

19.1. Germany Lucentis (Ranibizumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Germany Lucentis (Ranibizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Germany Lucentis (Ranibizumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Lucentis (Ranibizumab) Market

20.1. France Lucentis (Ranibizumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. France Lucentis (Ranibizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. France Lucentis (Ranibizumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Lucentis (Ranibizumab) Market

21.1. Eastern Europe Lucentis (Ranibizumab) Market Overview
21.2. Eastern Europe Lucentis (Ranibizumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Lucentis (Ranibizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Lucentis (Ranibizumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Lucentis (Ranibizumab) Market

22.1. North America Lucentis (Ranibizumab) Market Overview
22.2. North America Lucentis (Ranibizumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. North America Lucentis (Ranibizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.4. North America Lucentis (Ranibizumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Lucentis (Ranibizumab) Market

23.1. USA Lucentis (Ranibizumab) Market Overview
23.2. USA Lucentis (Ranibizumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. USA Lucentis (Ranibizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. USA Lucentis (Ranibizumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Lucentis (Ranibizumab) Market

24.1. Canada Lucentis (Ranibizumab) Market Overview
24.2. Canada Lucentis (Ranibizumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. Canada Lucentis (Ranibizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. Canada Lucentis (Ranibizumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Lucentis (Ranibizumab) Market

25.1. South America Lucentis (Ranibizumab) Market Overview
25.2. South America Lucentis (Ranibizumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. South America Lucentis (Ranibizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. South America Lucentis (Ranibizumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Lucentis (Ranibizumab) Market

26.1. Middle East Lucentis (Ranibizumab) Market Overview
26.2. Middle East Lucentis (Ranibizumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. Middle East Lucentis (Ranibizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. Middle East Lucentis (Ranibizumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Lucentis (Ranibizumab) Market

27.1. Africa Lucentis (Ranibizumab) Market Overview
27.2. Africa Lucentis (Ranibizumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Africa Lucentis (Ranibizumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.4. Africa Lucentis (Ranibizumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Lucentis (Ranibizumab) Market Competitive Landscape And Company Profiles

28.1. Lucentis (Ranibizumab) Market Competitive Landscape
28.2. Lucentis (Ranibizumab) Market Company Profiles
- 28.2.1. F.Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
- 28.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

29. Global Lucentis (Ranibizumab) Market Pipeline Analysis

29.1. High Level Clinic Trail Information

30. Global Lucentis (Ranibizumab) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Lucentis (Ranibizumab) Market

32. Recent Developments In The Lucentis (Ranibizumab) Market

33. Lucentis (Ranibizumab) Market High Potential Countries, Segments and Strategies

33.1 Lucentis (Ranibizumab) Market In 2029 - Countries Offering Most New Opportunities
33.2 Lucentis (Ranibizumab) Market In 2029 - Segments Offering Most New Opportunities
33.3 Lucentis (Ranibizumab) Market In 2029 - Growth Strategies
- 33.3.1 Market Trend Based Strategies
- 33.3.2 Competitor Strategies

34. Appendix

34.1. Abbreviations
34.2. Currencies
34.3. Historic And Forecast Inflation Rates
34.4. Research Inquiries
34.5. The Business Research Company
34.6. Copyright And Disclaimer